Subcutaneous Amifostine Safety Study

Summary

Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.

Timeline

Start

2002-01

Primary completion

—

Completion

2005-01

Drugs

Indications